PTGS2 and ovarian cancer: In a preclinical ovarian cancer model, celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, and ciglitazone, a PPARγ ligand, reduced tumor growth by decreasing angiogenesis through inhibited VEGF production in relation to PGE2 reduction [111].